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Abstract
The Princeton Consensus (Expert Panel) Conference is a multispecialty collaborative tradition dedicated to optimizing sexual
function and preserving cardiovascular health. The third Princeton Consensus met November 8 to 10, 2010, and had 2
primary objectives. The first objective focused on the evaluation and management of cardiovascular risk in men with erectile
dysfunction (ED) and no known cardiovascular disease (CVD), with particular emphasis on identification of men with ED
who may require additional cardiologic work-up. The second objective focused on reevaluation and modification of previous
recommendations for evaluation of cardiac risk associated with sexual activity in men with known CVD. The Panel’s
recommendations build on those developed during the first and second Princeton Consensus Conferences, first emphasizing
the use of exercise ability and stress testing to ensure that each man’s cardiovascular health is consistent with the physical
demands of sexual activity before prescribing treatment for ED, and second highlighting the link between ED and CVD,











the end of the article.
766 Mayo Clin Proc.  AugusT he Princeton Consensus Conference is amultispecialty collaborative tradition dedi-cated to optimizing sexual function and pre-
serving cardiovascular health. The first conference
convened in June 1999 to develop recommenda-
tions for clinical management of sexual dysfunction
in men and women with known cardiovascular dis-
ease (CVD). This conference also provided a multi-
disciplinary forum for evaluation of the potential
cardiovascular risk posed by sexual activity in at-
risk patients. The first Princeton Consensus Confer-
ence recommendations1 included stratification of
patients by level of cardiac risk associated with sex-
ual activity based on existing CVD. Those at low risk
could initiate or resume sexual activity and be
treated for sexual dysfunction. For those at high
risk, sexual activity was deferred until the cardiac
condition was stabilized. The second Princeton
Consensus Conference convened in June 2004 and
expanded the recommendations of the first confer-
ence to emphasize risk factor evaluation and lifestyle
management for all men with erectile dysfunction
(ED).2 The second conference recommendations
also incorporated new information on the appropri-
t 2012;87(8):766-778  http://dx.doi.org/10.1016/j.mayocp.2012.06.015 ate use of phosphodiesterase type 5 (PDE5) inhibi-
tors in men with ED and concomitant CVD.
The third Princeton Consensus Conference
took place November 8 to 10, 2010, in Miami
Beach, Florida. The group revisited and updated
their 2005 recommendations regarding the cardio-
vascular risk associated with sexual activity in men
with known CVD.2 In addition, the third conference
ocused on the predictive value of vasculogenic ED
n assigning cardiovascular risk in men of all ages,
ith the primary objective being development of an
pproach to cardiovascular risk assessment in
ounger men with ED and no known CVD. The role
f testosterone in erectile function and cardiovascu-
ar health and the utility of testosterone replacement
herapy (TRT) were also examined.
Recommendations were developed via the same
rocess used in the first and second conferences.1,2
Briefly, an international panel of 22 experts pro-
vided state-of-the-art presentations pertaining to
the epidemiologic and physiologic links among
hypogonadism, ED, and CVD; benefits and risks
of testosterone depletion and repletion; evalua-From the Department of
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ERECTILE DYSFUNCTION AND CARDIOVASCULAR DISEASErisk factors and assessment tools; and available
treatments for ED. After the presentations, a repre-
sentative consensus panel met to review the infor-
mation and, based on available scientific evidence,
to develop recommendations for clinical practice
and further research. The recommendations were
modified and finalized through electronic commu-
nication and were approved by final consensus of
the panel.
RECOMMENDATIONS
The recommendations of the third Princeton Con-
sensus Conference focus on (1) evaluation and man-
agement of cardiovascular risk in men with ED and
no known CVD, (2) reevaluation and modification
of the second conference recommendations for eval-
uation of cardiac risk associated with sexual activity
in men with known CVD, and (3) the role of TRT in
ED and CVD management.
EVALUATION AND MANAGEMENT OF
CARDIOVASCULAR RISK IN THE PATIENT WITH
ED WITH NO KNOWN CVD
The consensus panel defines cardiovascular risk as
the risk of morbid events over a 3- to 5-year interval
from the onset of ED (American College of Cardi-
ology Foundation/American Heart Association
[ACCF/AHA] class Ib)3,4 and provides recom-
mendations for the evaluation and management
of cardiovascular risk in men with ED and no
known CVD. The panel’s approach broadens the
use of the 2010 ACCF/AHA guideline for assess-
ment of cardiovascular risk in asymptomatic adults
to address an at-risk patient population that the
guideline does not mention: men with ED. The ra-
tionale for each step in the panel’s approach is de-
tailed herein. The 2010 ACCF/AHA guideline5 pro-
vides recommendations and levels of evidence
(LOEs) for some of the recommended assessments,
and we provide them for others.
Sexual Inquiry of All Men
● ED provides an opportunity for CVD risk reduction.6
● ED not only shares risk factors with CVD7,8 but
also is, in itself, an independent marker of in-
creased risk for CVD (ACCF/AHA class Ia).9-15
● ED is a marker of significantly increased risk of
CVD, coronary artery disease (CAD), stroke, and
all-cause mortality.
Incident ED has a similar or greater predictive
value for cardiovascular events as traditional risk
factors, such as family history of myocardial infarc-
tion (MI), smoking, and hyperlipidemia.16,17 Erec-
tile dysfunction commonly occurs in the presence of
Mayo Clin Proc.  August 2012;87(8):766-778  http://dx.doi.org/10
www.mayoclinicproceedings.orgsilent CAD,3,18-20 with a time window between ED
onset and a CAD event of 2 to 5 years (class Ia).3,4,21
Furthermore, evidence suggests that ED is predic-
tive of peripheral arterial disease (PAD)22 and
stroke.23 In a population-based study of men 40 to
0 years of age, addition of ED status to the
ramingham Risk Score (FRS) in a multivariate sta-
istical model resulted in reclassification of 5 of 78
ow-risk patients (5% risk) to intermediate risk
5% to 10% risk).9 In addition, data from the Olm-
sted County Study suggest that ED is far more pre-
dictive of CAD in men 40 to 49 years of age than in
older men,24 and the incidence of atherosclerotic
cardiovascular events in men younger than 40 years
with ED was more than 7 times the incidence in a
reference population representative of the general
male population in Western Australia.25 Thus, ED
may be particularly useful in assessing cardiovascu-
lar risk in younger men26 and in minorities,27 whose
isk may be underestimated by global risk assess-
ents such as the FRS. Finally, assessment of ED
ust include ED severity because more severe ED
as been associated with greater risk of major car-
iovascular events,28 CAD,23,29 extent of CAD,19,21,30
and risk of PAD (ACCF/AHA class Ia).22 These rec-
ommendations are supported by a meta-analysis of
12 prospective studies involving 36,744 men (Table
1).31 In this study and in a study of ED in men with
known CVD, ED was found to be an independent
marker of cardiovascular events and all-cause mor-
tality additional to conventional risk factors (eg, age,
weight, hypertension, diabetes, hyperlipidemia, and
cigarette smoking).
Limitations of the FRS in Men With ED
● ED is a marker of increased CVD risk independent
of the FRS.
The FRS is a useful tool for estimating the 10-
ear risk of MI or coronary death and is supported
y the 2010 ACCF/AHA guideline for assessment of
ardiovascular risk in asymptomatic adults (ACCF/
HA class I, LOE B).5 It incorporates age, sex, total
nd high-density lipoprotein (HDL) cholesterol lev-
ls, smoking status, systolic blood pressure (BP),
TABLE 1. Relative Risks for Men With Erectile Dysfun
Relative risk 95% Con
Overall 1.48 1.
Coronary heart disease 1.46 1.
Stroke 1.35 1.
All-cause mortality 1.19 1.
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768and use of antihypertensive medications.32 How-
ever, it is important to note that the Framingham
study and other long-term observational studies in-
clude few data from patients younger than 40 years.
Thus, the FRS may not adequately estimate risk in
younger patients. The FRS also lacks some impor-
tant risk factors (eg, family history, fasting glucose
level, serum creatinine level [estimated glomerular
filtration rate], urinary albumin to creatinine ratio,
and, potentially, testosterone level) that should be
considered when estimating cardiovascular risk in
men with ED. Therefore, although the consensus
panel recommends the FRS as a starting point for
estimating the likelihood of subclinical atheroscle-
rosis in men with ED, the presence of ED per se,
especially in men aged 30 to 60 years, should alert
the physician to the possibility of increased CVD
risk independently of the FRS. The checks recom-
mended should, therefore, be used to modify risk
after FRS determination in men with ED.
Recommended Assessments and Risk
Clarification
● A man with organic ED should be considered at
increased CVD risk until recommended checks
suggest otherwise.
● ED identifies increased CVD risk in the presence
or absence of CVD symptoms or history.
The consensus panel recommends the following
risk assessments, which may be used to identify men
with ED and no known CVD who may require ad-
ditional cardiologic work-up. In the broadest sense,
this risk refers to experiencing a significant cardiac
event, including MI, acute coronary syndromes, an-
gina pectoris, heart failure, and death.
● Patient history, including age, presence or ab-
sence of comorbid conditions (eg, abdominal obe-
sity, hypertension, dyslipidemia, prediabetes, and
symptoms suggestive of obstructive sleep apnea),
family history of premature atherothrombotic
CVD (father aged 55 years or mother aged 65
years; ACCF/AHA class I, LOE B), and lifestyle
factors (eg, diet, excessive use of alcohol, limited
physical activity, and smoking)
● Physical examination noting BP, waist circumfer-
ence (WC), body mass index (BMI), fundal arte-
rial changes, cardiac auscultation, carotid bruits,
and palpation of femoral and pedal pulses
● ED severity (International Index of Erectile Func-
tion score or Sexual Health Inventory of Men) and
duration
● Resting electrocardiogram (ACCF/AHA class IIa,
LOE C in asymptomatic adults with hypertension
or diabetes and ACCF/AHA class IIb, LOE C in
Mayo Clin Proc.  August 2012;8asymptomatic adults without hypertension or di-
abetes)
● Fasting plasma glucose level
● Serum creatinine level (estimated glomerular fil-
tration rate) and albumin to creatinine ratio
● Total testosterone (TT) level (before 11 AM)
● Plasma lipid levels (total, low-density lipoprotein,
and HDL cholesterol and triglyceride values)
Findings from a study of 4883 men and women
5 years and older who were followed up for 10
ears suggest that 9 of 10 new cases of diabetes
ould have been avoided if patients were in the
ow-risk group for each of 5 lifestyle factors (physi-
al activity, diet [combining intake of fiber, polyun-
aturated vs saturated fat, trans fats, and glycemic
ndex], smoking habits, alcohol use, and adiposity
measured by BMI or WC]).33 Recent evidence sug-
gests that measures of abdominal adiposity (eg, WC
and waist to hip ratio) are better predictors of adverse
cardiovascular outcomes than is BMI.34,35 Abdominal
obesity is associated with secretion of excess free fatty
acids, release of inflammatory cytokines, and reduced
secretion of adiponectin.36 Furthermore, diabetes is
ssociated with a 2-fold increase in the prevalence of
VD,37 and estimated glomerular filtration rates less
han 60 mL/min and urinary albumin to creatinine
atios greater than 10 mg/g are associated with in-
reased cardiovascular mortality independent of other
isk factors.38,39
The consensus panel recommends that testos-
erone levels be measured in all men with a diagno-
is of organic ED, especially in those for whom PDE5
nhibitor therapy failed.6 This recommendation may
be controversial, and it differs from the guideline
published by the American College of Physicians,40
which does not recommend for or against routine
hormonal blood tests or treatment in patients with
ED. However, the British Society for Sexual Medi-
cine and the International Society for Sexual Medi-
cine advocate testosterone measurements (2) in all
men with ED. The American College of Physicians
urges physicians to consider the presence or absence
of symptoms of hormonal dysfunction (eg, de-
creased libido and decreased spontaneous erection)
and of physical findings (eg, testicular or muscle
atrophy) when considering whether to measure tes-
tosterone levels in individual patients with ED. The
consensus panel recommendation for evaluation of
testosterone levels in all men with ED is based on
evidence from an accumulation of recent studies
linking low testosterone levels to ED and CVD.41
Testosterone is a key central and peripheral modu-
lator of erectile function in animal studies.42-45 Con-
istent with these observations, a single-center study
f 1050 men seeking new consultation for sexual


















ERECTILE DYSFUNCTION AND CARDIOVASCULAR DISEASEfrom 7000 men with ED in 9 large series, reported
serum testosterone levels less than 300 ng/dL (to
convert to nmol/L, multiply by 0.0347) in 12%, in-
cluding 4% before and 15% after age 50 years. Hy-
pogonadism is a potential cause of lack of response
to PDE5 inhibitor therapy,48,49 and TRT improves
response.49 This finding suggests that a minimal
level of testosterone is required for a complete effect
of PDE5 inhibitor therapy.49,50 However, testoster-
one assay methods differ, and there are no generally
accepted lower limits of normal TT.
Several epidemiologic studies have associated
low testosterone levels with increased all-cause and
cardiovascular mortality (Table 2).51-59 However, a
2010 meta-analysis limited to longitudinal (cohort)
studies in middle-aged men found no association
between endogenous TT levels and risk of CVD in
middle-aged men.60 A more recent study by Corona
et al61 found significant associations between low
TT levels and high estradiol levels and CVD in a
meta-analysis of 49 cross-sectional studies. Con-
versely, in a meta-analysis of 10 longitudinal stud-
ies, TT levels were significantly lower in patients
with incident overall and cardiovascular mortality
compared with controls, but there were no differ-
ences in baseline TT and estradiol levels between
cases and controls for incident CVD.60 The authors
of both studies acknowledged that low testosterone
levels may be a marker of poor general health rather
than CVD risk per se. Consistent with this notion,
androgen deficiency has been associated with insu-
lin resistance, type 2 diabetes mellitus, metabolic
syndrome, and increased deposition of visceral
fat.62-65 In the TIMES2 (Testosterone Replacement
In Hypogonadal Men With Either Metabolic Syn-
drome or Type 2 Diabetes) study, 6 to 12 months of
transdermal TRT (vs placebo) significantly im-
TABLE 2. Low Testosterone Levels and Increased Mo
Reference HR (95% CI) Study des
Shores et al,51 2006 1.88 (1.34-2.63) Retrospec
Laughlin et al,52 2008 1.40 (1.14-1.71) Prospectiv
1.38 (1.02-1.85)
Khaw et al,53 2007 2.29 (1.60-3.26) Prospectiv
Haring et al,54 2010 2.32 (1.38-3.89) Prospectiv
2.56 (1.15-6.52)
Malkin et al,55 2010 2.27 (1.45-3.60) Prospectiv
Tivesten et al,56 2009 1.65 (1.29-2.12) Prospectiv
Menke et al,57 2010 1.43 (1.09-1.87) Prospectiv
Vikan et al,58 2009 1.24 (1.01-1.54) Prospectiv
Corona et al,59 2010 7.1 (1.8-28.6) Prospectiv
CI  confidence interval; CVD  cardiovascular disease; HR proved insulin resistance and glycemic control in a
Mayo Clin Proc.  August 2012;87(8):766-778  http://dx.doi.org/10
www.mayoclinicproceedings.orglarge randomized study of hypogonadal men with
type 2 diabetes mellitus (ACCF/AHA class Ib).66 A
eta-analysis of 5 other randomized controlled tri-
ls (including 3 placebo-controlled trials) with
ean follow-up of 58 weeks found that TRT was
ssociated with a significant reduction in fasting
lasma glucose levels, homeostasis model assess-
ent of insulin resistance index, triglycerides, and
C. An increase in HDL cholesterol level was also
bserved, whereas no significant differences were
bserved for total cholesterol level, BP, or BMI.67 In
summary, the panel recommended:
● All men with ED should have their cardiovascular
risk assessed.
● Testosterone level should be routinely measured.
reatment, Additional Cardiovascular Evaluation,
nd Referral
● In all patients, lifestyle changes are likely to re-
duce cardiovascular risk and improve erectile
function.
● All men with ED should have their testosterone
level measured and replacement considered when
appropriate.
A meta-analysis of lifestyle modification strength-
ned the evidence for improvement in ED and main-
enance of sexual function as well as cardiovascular
isk reduction in addition to previous reviews.31
Lifestyle advice should include the following: smok-
ing cessation, regular dynamic exercise, weight loss,
a healthy diet (eg, the Mediterranean diet, which
emphasizes fruits, vegetables, beans and legumes,
whole grains, nuts, fish, poultry, lean red meat,
cheese, and yogurt),68 and moderate alcohol con-
y Rates in Recent Publications With Populations Greate
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770men, in which number of units is calculated as per-
centage of alcohol  volume/1000).
Although compliance with lifestyle advice can
be difficult to achieve, population-based studies
suggest that changes in lifestyle may be most impor-
tant for primary prevention. Managing cardiovascu-
lar risk with lifestyle change also permits avoidance
or reduction of adverse drug effects. In a meta-anal-
ysis of prospective cohort studies of patients with
coronary heart disease, smoking cessation reduced
total mortality by 36%.69 The pleiotropic effects of
physical activity (eg, improved lipid profiles, BP,
glucose-insulin homeostasis, endothelial function,
inflammatory markers, and psychological well-be-
ing) 70-73 likely account for 30% to 50% reductions
in incident type 2 diabetes and coronary heart dis-
ease in physically active vs sedentary individuals.72
Diet can reduce death from coronary heart disease
by up to 36% and can improve many established
risk factors.73
Consistent with the British Society for Sexual
Medicine’s guidelines on the management of ED,74
the Third International Consultation of Sexual Med-
icine,75 the Endocrine Society guidelines,41 and a
combined guidance of the International Society of
Andrology, International Society for the Study of the
Aging Male, European Association of Urology, Eu-
ropean Academy of Andrology, and American Soci-
ety of Andrology,76 the panel agreed that a TT level
greater than 350 ng/dL does not usually require sub-
stitution and that men with TT levels less than 230
ng/dL usually benefit from TRT. If there are no con-
traindications, symptomatic men (decreased libido
or ED) with TT levels of 231 to 346 ng/dL may be
considered for a 4- to 6-month trial of TRT but only
after careful discussion about the potential risks and
benefits. Beyond 6 months, TRT should be contin-
ued only in cases of clinical benefit.77 Caution is
warranted in men with a history of congestive heart
failure (risk of fluid retention); repletion goals
should be in the middle range (ie, 350-600 ng/dL)
for this group. In patients older than 70 years and
those with chronic illness, the consensus panel sug-
gests use of an easily titratable testosterone formu-
lation (eg, gel, spray, or patch) rather than interme-
diate and long-acting injectable formulations. Also
note that randomized trials are needed to establish
the risks and benefits of TRT regarding cardiovascu-
lar risk and all-cause mortality. Baseline hematocrit
and prostate-specific antigen testing and 6-month
monitoring are necessary.
As the consensus panel considers all men with ED
who are older than 30 years to be at increased CVD
risk, a thorough noninvasive and, when indicated, in-
vasive evaluation of CVD status is recommended.
A collaborative management approach incorpo-
rating primary care and cardiology expertise should t
Mayo Clin Proc.  August 2012;8include lifestyle advice and pharmacotherapy to ag-
gressively control cardiovascular risk factors (eg,
BP, hyperlipidemia, and hyperglycemia), with
follow-up at routine intervals.
Noninvasive cardiovascular evaluation may in-
clude measurement of biomarkers and physiologic
stress testing for ischemia or anatomical clarification
by coronary computed tomographic angiography
(CCTA) for diagnosis of asymptomatic or undiag-
nosed CAD.78-81 This evaluation can be requested
y a cardiologist, primary care physician, androlo-
ist, or urologist with specialized training in cardio-
ascular risk assessment. The 2010 ACCF/AHA
uideline for assessment of cardiovascular risk in
symptomatic adults5 provides recommendations
nd LOEs for the following techniques:
● Exercise stress testing (EST) (ACCF/AHA class
IIb, LOE B in asymptomatic, intermediate-risk
adults, particularly when nonelectrocardiogram
markers are considered [ie, exercise capacity]
rather than ST-segment changes)5,82
● Carotid intima-media thickness (CIMT) (ACCF/
AHA class IIa, LOE B in asymptomatic, interme-
diate-risk adults)
● Computed tomography for coronary artery cal-
cium scoring (CACS) (ACCF/AHA class IIa, LOE
B in asymptomatic, intermediate-risk men 40
years old; ACCF/AHA class IIb, LOE B in low- to
intermediate-risk [6%-10% 10-year risk] men
40 years old)
● Ankle-brachial index (ABI) (ACCF/AHA class IIa,
LOE B in asymptomatic, intermediate-risk adults)
● CCTA (ACCF/AHA class III, LOE C in asymptom-
atic patients)
● Pulse wave velocity (PWV) (ACCF/AHA class III,
LOE C in asymptomatic patients)
● Noninvasive assessment of endothelial function (ie,
brachial artery flow-mediated dilation) (ACCF/AHA
class III, LOE B in asymptomatic adults)
Despite its limitations in detecting CVD without
ignificant stenosis, EST (with or without imaging)
an further define the cardiovascular risk in pa-
ients with ED and may be particularly helpful for
dentifying silent CAD in patients with diabetes.
n a study of patients with type 2 diabetes, ED was
ignificantly more prevalent in men with silent CAD
33.8%) identified by EST than in those without
ilent CAD (4.7%).18 Chemical stress tests (dipyri-
amole [Persantine, Boehringer Ingellheim GmbH,
ngelheim, Germany] or adenosine with nuclear im-
ging) are appropriate for patients who cannot com-
lete an EST (eg, inability to exercise due to a dis-
bling condition such as arthritis). If the baseline
lectrocardiogram makes EST unavailable or nonin-
































ERECTILE DYSFUNCTION AND CARDIOVASCULAR DISEASEral to a cardiologist or a practice with cardiology
expertise for further evaluation.
The order of testing that men with ED should
undergo is the decision of the primary care physi-
cian or cardiologist. However, it makes sense for
noninvasive tests (ie, EST, CIMT, and ABI) to be
performed before those that require radiation/con-
trast (eg, CCTA and CACS). However, CCTA or
CACS as the first test may be appropriate for
younger patients (aged 50 years) with a family
history of CVD, severe ED, diabetes, or multiple risk
factors. Invasive coronary angiography should be
considered when noninvasive evaluation suggests
significantly increased CVD risk.
The 2010 ACCF/AHA guideline asserts that it is
“reasonable” to perform CIMT, CACS, and ABI dur-
ing assessment of intermediate-risk patients.5 The
Society for Heart Attack Prevention and Eradication
task force issued a stronger recommendation, sug-
gesting that all asymptomatic men 45 to 75 years of
age and women 55 to 75 years of age who do not
have very-low-risk characteristics (ie, absence of any
traditional cardiovascular risk factors) or a docu-
mented history of CVD undergo CACS or CIMT
screening for the detection of subclinical atheroscle-
rosis.83 In an analysis from the Atherosclerosis Risk
in Communities study, addition of CIMT and
plaque detection via ultrasonography to traditional
risk factors improved coronary heart disease risk
prediction.84 In the Multi-Ethnic Study of Athero-
sclerosis, CACS was a better predictor of CVD than
was CIMT.85 In a meta-analysis of 16 population-
based cohort studies, a low ABI (0.90) was asso-
ciated with approximately twice the 10-year total
mortality, cardiovascular mortality, and major cor-
onary event rates compared with the overall rate in
each FRS category,86 suggesting that ABI assessment
may improve cardiovascular risk prediction beyond
the FRS. Although the ACCF/AHA does not cur-
rently recommend assessment of arterial stiffness
(eg, PWV) for cardiovascular risk determination in
asymptomatic individuals, a meta-analysis of 17
longitudinal studies (mean follow-up, 7.7 years)
showed that participants with high aortic PWV were
at higher risk for total cardiovascular events, cardio-
vascular mortality, and all-cause mortality com-
pared with participants with low PWV.87 Similarly,
impaired endothelial dysfunction detected by En-
doPAT (Itamar Medical Ltd, Caesarea, Israel) was an
independent predictor of cardiac death, MI, revas-
cularization or cardiac hospitalization in symptom-
atic outpatients over 7-year follow-up.88 Similarly,
endothelial function assessed in the brachial artery
by flow-mediated dilation89,90 or in the forearm mi-
crovasculature by Doppler91 predicted outcome in-
dependently of FRS. However, the role of measures a
Mayo Clin Proc.  August 2012;87(8):766-778  http://dx.doi.org/10
www.mayoclinicproceedings.orgof endothelial function in the evaluation of men with
ED has yet to be established.
Assessment of circulating or noncirculating bio-
markers may also help detect subclinical CVD in the
indeterminate-risk patient. Consistent with the 2010
ACCF/AHA guideline for assessment of cardiovascular
risk in asymptomatic adults,5 the consensus panel rec-
mmends that physicians consider evaluation of the
ollowing nontraditional risk factors: high-sensitivity
-reactive protein (hsCRP) level (ACCF/AHA class IIb,
OE B in asymptomatic, intermediate-risk men 50
ears),5 glycated hemoglobin level (ACCF/AHA class
Ib, LOE B in asymptomatic adults without a diagnosis
f diabetes),5 urinary albumin excretion (ACCF/AHA
class IIa, LOE B in asymptomatic adults with hyperten-
sion or diabetes; and ACCF/AHA class IIb, LOE B in
asymptomatic, intermediate-risk adults without hy-
pertension or diabetes),5 serum uric acid level, and
lipoprotein-associated phospholipase A2 level (ACCF/
AHA class IIb, LOE B in asymptomatic, intermediate-
risk adults).5
The hsCRP level is an independent predictor of
ncident coronary events after adjustment for tradi-
ional risk factors (ie, age, total cholesterol level,
DL cholesterol level, smoking status, BMI, diabe-
es, history of hypertension, exercise level, and fam-
ly history of coronary disease).92-94 Thus, in 2003,
he Centers for Disease Control and Prevention and
he AHA endorsed measurement of the hsCRP level
s an adjunct to global risk prediction, particularly
n patients at intermediate risk (10%-20% over 10
ears).95 More recently, the hsCRP level improved
he predictive value of the FRS in patients at high
isk for coronary heart disease.96 The independent
prognostic value of the hsCRP level was also evident
in a meta-analysis of 160,309 people without a his-
tory of vascular disease (ie, 1.31 million person-
years at risk and 27,769 fatal or nonfatal disease
outcomes) from 54 long-term prospective studies.97
Ridker98 reviewed evidence that hsCRP level cor-
rectly reclassifies a substantial proportion of patients
at intermediate risk for CVD into clinically relevant
higher- or lower-risk groups.
Although not specifically addressed in the 2010
ACCF/AHA guideline for assessment of cardiovas-
cular risk in asymptomatic adults,5 the consensus
anel recommends evaluation of serum uric acid
evels. Similar to hsCRP levels, the recent literature
upports the serum uric acid level as an inexpensive
arker of increased cardiovascular risk.99 There is
nconsistency regarding the incremental benefit of
dding the glycated hemoglobin level or microalbu-
inuria to standard risk factors in prediction of
VD and reclassification of cardiovascular risk.
owever, a recent analysis of data from the Athero-
clerosis Risk in Communities study showed that











772tion models incorporating traditional risk factors
and the fasting glucose level improved coronary
heart disease risk prediction in nondiabetic patients
with no history of CVD.100 In a meta-analysis of 26
cohort studies, microalbuminuria was associated
with a 50% greater risk of coronary heart disease,
and macroalbuminuria more than doubled coronary
heart disease risk.101 Finally, the lipoprotein-asso-
ciated phospholipase A2 level seems to be an inde-
pendent predictor of CVD events in apparently
healthy adults after adjustment for hsCRP levels and
standard risk factors.102-105 The 2010 ACCF/AHA
guideline5, p.e66 states that measurement of lipo-
protein-associated phospholipase A2 “might be rea-
sonable for cardiovascular risk assessment in inter-
mediate-risk asymptomatic adults.”
MANAGEMENT OF ED IN THE PATIENT WITH
KNOWN CVD
The objective of this algorithm is to estimate the
cardiovascular risk associated with sexual activity in
patients with ED and known CVD (Figure). Herein,
risk refers to the likelihood of mortal or morbid
events during or shortly after sexual activity. The
panel’s recommendations are similar to those devel-
oped during the first and second Princeton Consen-
sus Conferences.1,2 However, the current recom-
mendations classify patients with New York Heart
Association (NYHA) class II as low risk rather than
intermediate risk as in previous recommendations.
Indeterminate risk High risk
Cardiologist
 risk High risk
Failass




erectile dysfunction (ED) in all men with ED, especially
scular disease. aSexual activity is equivalent to walking
tes or briskly climbing 2 flights of stairs in 10 seconds.
t to 4 minutes of the Bruce treadmill protocol.Mayo Clin Proc.  August 2012;8Patients with NYHA class III have been moved from
high to intermediate risk. Patients with mild, stable
angina and those with past MI (6-8 weeks) have
been reclassified as intermediate risk rather than low
risk as in previous recommendations.
Sexual Inquiry
As reviewed previously herein, ED and CVD share risk
factors, and ED is an independent predictor of CVD.
Thus, assessment of sexual function should be incor-
porated into the initial cardiovascular evaluation for all
men, regardless of the presence or absence of known
CVD.
Exercise Ability and Sexual Activity Risk
Stratification
A recent meta-analysis of 10 studies established a
significant association between acute cardiac events
and episodic physical and sexual activity that was
attenuated among individuals with high levels of
habitual physical activity.106 Thus, exercise ability
iscerned by review of patient history may guide the
hysician to an estimate of cardiovascular risk asso-
iated with sexual activity. Exercise tolerance
hould be established before the initiation of ED
herapy in all men regardless of cardiovascular risk.
embers of the Princeton III Consensus contrib-
ted to “Sexual Activity and Cardiovascular Dis-
ase,” the focus of an AHA Scientific Statement.107
To aid practice, common patient profiles are pro-
vided for each level of risk.
Low-Risk Patients. As in previous recommenda-
tions, the low-risk group is limited to patients for
whom sexual activity does not represent significant
cardiac risk. These patients can generally perform
exercise of modest intensity without symptoms.
Low-risk patients include successfully revascular-
ized (eg, via coronary artery bypass grafting, stent-
ing, or angioplasty) individuals, patients with
asymptomatic controlled hypertension, those with
mild valvular disease, and patients with left ventric-
ular dysfunction/heart failure (NYHA classes I and
II) who achieved 5 metabolic equivalents of the task
(Mets) without ischemia on recent exercise testing.
High-Risk Patients. High-risk patients are those
with cardiac conditions severe or unstable enough
to pose a significant risk with sexual activity. Most
are moderately or severely symptomatic. Common
high-risk patient profiles include unstable or refrac-
tory angina pectoris, uncontrolled hypertension,
congestive heart failure (NYHA class IV), recent MI
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ERECTILE DYSFUNCTION AND CARDIOVASCULAR DISEASEimplanted internal cardioverter defibrillator with
frequent shocks, and poorly controlled atrial fibril-
lation), obstructive hypertrophic cardiomyopathy
with severe symptoms, and moderate to severe valve
disease, particularly aortic stenosis.
Indeterminate-Risk Patients. Further evaluation
using EST is required for indeterminate-risk pa-
tients before resuming sexual activity. Sexual activ-
ity between couples in a longstanding relationship
equates to approximately 3 Mets. Completing 4
minutes of the standard Bruce treadmill protocol
(5-6 Mets) without symptoms, arrhythmias, or a fall
in systolic BP identifies the safety of sexual activ-
ity.1,2,6 Based on stress test results, they will be re-
assigned to low- or high-risk groups as recom-
mended after the first and second Princeton
Consensus Conferences. Chemical stress tests (eg,
dipyridamole or adenosine with nuclear imaging)
are appropriate if the patient cannot complete a
standard exercise test (eg, owing to a disabling con-
dition such as arthritis). Indeterminate-risk patients
include those with mild or moderate stable angina
pectoris, past MI (2-8 wks) without intervention
awaiting exercise electrocardiography, congestive
heart failure (NYHA class III), and noncardiac se-
quelae of atherosclerotic disease (eg, PAD and a his-
tory of stroke or transient ischemic attack); this pa-
tient with ED may require assessment for additional
vascular disease using CIMT or the ABI and subse-
quent reclassification to low or high risk.
ED Treatment (Low-Risk Patient) or Referral to a
Cardiologist (High-Risk Patient)
● Most low-risk patients can initiate or resume sex-
ual activity and begin ED treatment without fur-
ther testing or evaluation.
The PDE5 inhibitors (eg, sildenafil, tadalafil,
and vardenafil) are widely used to treat ED. Their
safety and appropriate use was reviewed in the sec-
ond Princeton Consensus Conference recommen-
dations,2 and more recent analyses of placebo-con-
trolled and postmarketing surveillance data have
demonstrated no new concerns regarding cardio-
vascular events.108,109 In fact, a variety of studies
have demonstrated a potential role for PDE5 inhibi-
tion in the management of hypertension110-113 and
endothelial dysfunction114-116 in patients at risk for
CVD. Effects on endothelial function are believed to
underlie the beneficial effect of PDE5 inhibition in
patients with pulmonary hypertension, for which
sildenafil and tadalafil are licensed for use. Addi-
tional considerations for treatment of ED should in-
clude TRT for men with low (230 ng/dL) or intermedi-
ate (230-350 ng/dL) serum TT levels (either as initial
Mayo Clin Proc.  August 2012;87(8):766-778  http://dx.doi.org/10
www.mayoclinicproceedings.orgtreatment or added to PDE5 inhibitor therapy after
PDE5 inhibitor failure),49,117 non–PDE5 inhibitor ap-
proaches,2 exercise and weight loss,118,119 and partner
and relationship factors.120-123
Management of ED should always be consid-
red secondary to maintaining cardiovascular func-
ion. Thus, treatment for ED should not negatively
ffect cardiovascular health. Conversely, potential
ffects on erectile function of agents used to treat
ardiovascular risk factors should be considered.
or example, the -blocker nebivolol, which has
direct vasodilating properties, is less likely to cause
ED than are other -blockers.124-126 Angiotensin
eceptor blockers are also less likely to cause ED
han are other antihypertensive agents (eg, diuret-
cs).127,128 There have been several reports of im-
rovements in erectile function among men using
tatins with and without PDE5 inhibitors.129-132
However, these findings are not consistent with
those of Solomon et al,133 who reported new-onset
ED in 22% of 93 high-risk men after 6 months of
statin use. Placebo-controlled studies of erectile
function in men taking medications to control other
cardiovascular risk factors are lacking.
In high-risk patients, sexual activity should be
deferred until the cardiac condition has been stabi-
lized and sexual activity can be safely resumed.
These patients should be referred to a cardiologist
for further evaluation and should be managed
with a collaborative approach to primary preven-
tion. In all cases, patient follow-up and reassess-
ment is recommended.
RECOMMENDATIONS
Consistent with other guidelines, the recommenda-
tions of the third Princeton Consensus Panel em-
phasize an approach to risk assessment that inte-
grates multiple aspects of cardiometabolic health.
Sexual function should be incorporated into CVD
risk assessment for all men, and ED may allow iden-
tification of at-risk men who require further cardio-
vascular evaluation. The scientific evidence suggests
that a comprehensive approach to cardiovascular
risk reduction will improve overall vascular health,
including sexual function. Similar to the first and
second Princeton Consensus panels, the third
Princeton Consensus also provides an approach to
ensuring that each man’s cardiovascular health is
consistent with the physical demands of sexual ac-
tivity before prescribing treatment for ED. Finally,
the panel encourages a collaborative approach to the
management of men’s sexual function and cardio-
vascular risk, incorporating general, urologic, endo-
crine, and cardiologic expertise.
Abbreviations and Acronyms ABI  ankle-brachial in-






















































774tion; AHA  American Heart Association; BMI  body
mass index; BP  blood pressure; CACS  coronary artery
calcium scoring; CAD  coronary artery disease; CCTA 
coronary computed tomographic angiography; CIMT  ca-
rotid intima-media thickness; CVD  cardiovascular dis-
ease; ED  erectile dysfunction; EST  exercise stress
testing; FRS  Framingham Risk Score; HDL  high-den-
sity lipoprotein; hsCRP  high-sensitivity C-reactive pro-
tein; LOE  level of evidence; Mets  metabolic equiva-
lents of the task; MI  myocardial infarction; NYHA  New
York Heart Association; PAD  peripheral artery disease;
PDE5  phosphodiesterase type 5; PWV  pulse wave
velocity; TRT  testosterone replacement therapy; TT 
total testosterone; WC  waist circumference
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